IFRX InflaRx N.V.

Nasdaq inflarx.de


$ 1.28 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 11:56:49 EDT
QQQ $ 609.14 $ 0.00 (0 %)
DIA $ 466.15 $ 0.00 (0 %)
SPY $ 670.30 $ 0.00 (0 %)
TLT $ 91.36 $ 0.00 (0 %)
GLD $ 381.23 $ 0.00 (0 %)
$ 1.27
$ 1.31
$ 1.26 x 18
$ 1.32 x 100
$ 1.27 - $ 1.34
$ 0.71 - $ 2.82
743,435
na
74.78M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inflarx-regains-nasdaq-compliance
InflaRx Regains Nasdaq Compliance
09/12/2025 12:36:51

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement s...

 top-4-biotech-stocks-set-for-a-breakout-momentum-scores-surge

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Ed...

 hc-wainwright--co-assumes-inflarx-at-buy-announces-price-target-of-6

HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of...

 inflarx-q2-eps-024-misses-017-estimate-sales-44708k-miss-50167k-estimate

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by ...

 oppenheimer-maintains-outperform-on-inflarx-lowers-price-target-to-3

Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 ...

 inflarx-ends-lead-asset-development-after-failed-study-for-rare-and-painful-skin-disease

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cas...

 inflarx-halts-vilobelimab-phase-3-trial-in-pyoderma-gangrenosum-after-futility-finding-in-interim-analysis

the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelima...

 oppenheimer-initiates-coverage-on-inflarx-with-outperform-rating-announces-price-target-of-6

Oppenheimer analyst Andreas Argyrides initiates coverage on InflaRx (NASDAQ:IFRX) with a Outperform rating and announces Pri...

 inflarx-q1-eps-014-beats-019-estimate

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26...

 preview-inflarxs-earnings
Preview: InflaRx's Earnings
05/06/2025 21:01:42

 cantor-fitzgerald-initiates-coverage-on-inflarx-with-overweight-rating-announces-price-target-of-10

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on InflaRx (NASDAQ:IFRX) with a Overweight rating and announce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION